Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00518089 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 859
- Enrollment target
NCT00518089: Completed Phase 3 study, sponsored by Allergan.
NCT00518089 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 859 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00518089, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 859 participants
- Enrollment target
Study Summary
The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis
Primary Outcome
Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye up to Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe).
Interventions
- DRUG placebo eye drops
- DRUG Gatifloxacin 0.5% eye drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 859 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-01 |
| Phase | Phase 3 |
What the finished NCT00518089 record still lists
NCT00518089 is an interventional study that assigns participants to a tested intervention. The registered 859 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo eye drops is the first listed.
NCT00518089 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00518089 about?
NCT00518089 is a clinical study titled "A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis". The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis
What is the current status of trial NCT00518089?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 859 participants. The study started on 2008-02. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00518089?
The interventions under investigation include: placebo eye drops (DRUG), Gatifloxacin 0.5% eye drops (DRUG).
Who is sponsoring clinical trial NCT00518089?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00518089's enrollment target sits among peer trials
859 383rd of 2000 higher than 1,618 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04541381 · 860 participants · NA
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
- NCT05211895 · 860 participants · Phase 3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
- NCT06161025 · 860 participants · Phase 2
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- NCT06541574 · 860 participants · Phase 2
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia